Switching to A 6-Monthly Triptorelin Formulation for Prostate Cancer (Pca) Reduces Patient–Nhs Interactions and Hospital Resource use- Real World Evidence (Rwe) from Project Deserve (Decapeptyl Service Evaluation)
Abstract
Authors
P Cornford K Jefferson O Cole JS Gilbody V Nayar G Auddy